High expression of microRNA‑31 and its host gene LOC554202 predict favorable outcomes in patients with colorectal cancer treated with oxaliplatin

Abstract

The expression levels of microRNA‑31 (miR‑31) and LOC554202 have been previously investigated in colorectal cancer (CRC) and their oncogenic and/or tumor suppressive roles have been described. The aim of the present study was to examine the role of miR‑31 and its host gene LOC554202 in the prognosis of patients with CRC. Patients with CRC treated with oxaliplatin‑based chemotherapy between June 2005 and March 2010 were recruited to the First Affiliated Hospital of China Medical University. Tumor and adjacent mucosal tissues were collected. The detection of miR‑31 and/or LOC554202 was performed with probe hybridization targeting. Correlation analysis was performed among the expression levels of miR‑31, LOC554202, and their association with clinicopathological parameters and/or survival rates. miR‑31 and LOC554202 were expressed at high levels in CRC (P<0.01) compared with adjacent intestinal mucosa. A linear correlation was noted for the two markers in CRC tissues (P<0.01). The expression of miR‑31 was significantly higher in adenocarcinoma than in the adjacent intestinal mucosa (P<0.01), whereas the expression of LOC554202 was significantly higher in the adenocarcinoma and the rectal cancer tissue regions (P<0.01). The high expression levels of miR‑31 and LOC554202 were associated with high disease‑free survival (DFS) and overall survival (OS) rates (P<0.05). Associations between the increase in DFS and OS and the elevated expression levels of miR‑31 and LOC554202 were present in patients with colon cancer but not in patients with rectal cancer (P<0.05). These data indicated that miR‑31 and LOC554202 may be potential markers for evaluation of the prognosis of patients treated with oxaliplatin‑based chemotherapy.

The predictive value of lncRNA MIR31HG expression on clinical outcomes in patients with solid malignant tumors

“…In CRC, the MIR31HG expression was negatively correlated with unfavorable prognosis, as indicated by advanced pathologic stage, and lager tumor size [19]. Consistently, Li Y et al found that high expression of MIR31HG predict high OS and DFS in CRC patients treated with oxaliplatin [32]. Given the prognostic significance of MIR31HG in cancers, in the current study, we firstly explored the association between MIR31HG level and clinical outcomes by performing a meta-analysis containing seventeen literatures with 2573 patients.…”

“…Specifically, MIR31HG was found elevated expressed in breast cancer [13], cervical cancer [28], chordoma [16], osteosarcoma [15], lung cancer [2,23,41], OSCC [4], PDAC [7], VSCC [29] and LSCC [36,42,43]. Nevertheless, the expression levels of MIR31HG was reported down-regulated in triple-negative breast cancer (TNBC) cell lines of basal subtype [27], bladder cancer [26], gastric cancer [25], CRC [32,33], and HCC [6]. Besides, abnormal expression of MIR31HG was deemed as potential biomarker to reflect the clinicopathological characteristics and prognostic outcomes of cancer patients [28].…”

“…According to the screening criteria, seventeen articles comprising 2573 patients were included in our study [1,2,4,6,15,17,19,23,25,26,[28][29][30][31][32][33]36]. All the included studies were related to lncRNA MIR31HG in cancer and comprised clinical data.…”

“…On the contrary, another study revealed that MIR31HG appeared to have lower expression in ESCC tissues and patients with reduced MIR31HG were correlated with malignant clinical features. The contradictory expression patterns of MIR31HG were also found in breast cancer [13,27], CRC [19,32,33] and gastric cancer [25,34]. In view of these conflicting data, for the first time, we performed this comprehensive meta-analysis of the current evidences in order to determine the predictive value of MIR31HG in various carcinomas.…”

The predictive value of lncRNA MIR31HG expression on clinical outcomes in patients with solid malignant tumors

“…On the contrary, another study revealed that MIR31HG appeared to have lower expression in ESCC tissues and patients with reduced MIR31HG were correlated with malignant clinical features. The contradictory expression patterns of MIR31HG were also found in breast cancer (13,27), CRC (19,32,33) and gastric cancer (25,34). In view of these conflicting data, for the first time, we performed this comprehensive metaanalysis of the current evidences in order to determine the predictive value of MIR31HG in various carcinomas.…”